Literature DB >> 6236221

Faulty association of alpha- and beta-subunits in some forms of beta-hexosaminidase A deficiency.

A d'Azzo, R L Proia, E H Kolodny, M M Kaback, E F Neufeld.   

Abstract

We have previously described the kinetics of association of the alpha- and beta-subunits of beta-hexosaminidase A in intact cultured human fibroblasts, using biosynthetic labeling and immunoprecipitation with antisera that distinguish between monomeric and associated alpha-chains (Proia, R. L., d'Azzo, A., and Neufeld, E. F. (1984) J. Biol. Chem. 259, 3350-3354). We now show lack of alpha-beta association in fibroblasts of several individuals deficient in beta-hexosaminidase A (5 patients with nonclassic forms of Tay-Sachs disease and 2 asymptomatic siblings). Defective association was accompanied by markedly reduced (less than one-tenth of normal) conversion of the alpha-chain precursor of Mr = 67,000 to the mature lysosomal form of Mr = 54,000. Analysis by hybridization with fibroblasts lacking the alpha- or beta-chain showed that the association defect resided in the alpha-chain. Most of the cell strains studied also had decreased synthesis of the alpha-chain, suggesting compound heterozygosity with the Ashkenazi Tay-Sachs (no synthesis) allele. An unusual feature of the association defect is the variability in the resulting clinical manifestations, even within families, implying that other factors determine the adequacy of the residual associated beta-hexosaminidase A in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6236221

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

Review 2.  Variable clinical presentation in lysosomal storage disorders.

Authors:  M Beck
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

3.  beta-Hexosaminidase isozymes from cells cotransfected with alpha and beta cDNA constructs: analysis of the alpha-subunit missense mutation associated with the adult form of Tay-Sachs disease.

Authors:  C A Brown; D J Mahuran
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

4.  Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes.

Authors:  M E Grace; A Berg; G S He; L Goldberg; M Horowitz; G A Grabowski
Journal:  Am J Hum Genet       Date:  1991-09       Impact factor: 11.025

Review 5.  Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells.

Authors:  Michael B Tropak; Don Mahuran
Journal:  FEBS J       Date:  2007-10       Impact factor: 5.542

Review 6.  [Sphingolipid storage diseases of the central nervous system: bases of biochemical and clinical heterogeneity].

Authors:  K Sandhoff; L Quintern
Journal:  Naturwissenschaften       Date:  1988-03

7.  Tay-Sachs disease with atypical chronic course and limited brain storage: alpha-locus hexosaminidase genetic compound.

Authors:  M Philippart; R E Carrel; B H Landing
Journal:  Neurochem Res       Date:  1995-11       Impact factor: 3.996

8.  Two abnormalities of hexosaminidase A in clinically normal individuals.

Authors:  E E Grebner; D A Mansfield; S S Raghavan; E H Kolodny; A d'Azzo; E F Neufeld; L G Jackson
Journal:  Am J Hum Genet       Date:  1986-04       Impact factor: 11.025

9.  GM2-ganglioside metabolism in hexosaminidase A deficiency states: determination in situ using labeled GM2 added to fibroblast cultures.

Authors:  S S Raghavan; A Krusell; J Krusell; T A Lyerla; E H Kolodny
Journal:  Am J Hum Genet       Date:  1985-11       Impact factor: 11.025

10.  The presence of a reduced amount of 32-kd "protective" protein is a distinct biochemical finding in late infantile galactosialidosis.

Authors:  P Strisciuglio; G Parenti; C Giudice; S Lijoi; A T Hoogeveen; A d'Azzo
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.